Before joining Novartis, Jay Bradner was a cancer researcher and pioneer of the growing trend toward open scientific innovation. He believes that in science, more minds are better. The more people working on tough scientific puzzles, the more likely they will be to find solutions. Now, as President of the Novartis Institutes for BioMedical Research (NIBR), he is applying this mindset to accelerate the process of drug discovery and development, an effort that takes good ideas from the lab and translates them into safe and effective medicines that fight disease. Over the past two years, NIBR has launched a series of open science initiatives and formed multiple collaborations with the entrepreneurial biotechnology community. Join Jay and Jonathan Rockoff of the Wall Street Journal for a discussion about this new direction for research and early development at one of the world's top biopharmaceutical companies.